Next, we showed that mEHT had an additive effect on the cell death induced by the p53-activating agent nutlin-3a, demonstrating that mEHT can be a powerful tool for augmenting the tumor-killing effect of treatment modalities targeting p53. The gene discussed is TP53; the disease is neoplasm.